Is TVRD or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media refer more to TVRD or ALDX?

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Tvardi Therapeutics' score of 0.16 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer JATT or TVRD?

Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 791.09%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has better earnings and valuation, JATT or TVRD?

JATT Acquisition has higher earnings, but lower revenue than Tvardi Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Tvardi Therapeutics $7.14M 2.65 -$18.21M -$3.10 N/A

Is JATT or TVRD more profitable?

JATT Acquisition's return on equity of -49.58% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Tvardi Therapeutics N/A -64.17% -43.90%

Is TVRD or BMEA more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Biomea Fusion N/A -265.37% -103.96%

Does the media prefer TVRD or BMEA?

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Biomea Fusion. Tvardi Therapeutics' average media sentiment score of 0.16 beat Biomea Fusion's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TVRD or KLRS more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Kalaris Therapeutics N/A -72.78% -43.49%

Does the media favor TVRD or KLRS?

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Kalaris Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.16 beat Kalaris Therapeutics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tvardi Therapeutics (TVRD) Competitors

$2.02 -0.08 (-3.81%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.04 (+1.93%)

As of 07:02 AM Eastern

Compare

TVRD vs. ALDX, AADI, JATT, BMEA, and KLRS

Should you buy Tvardi Therapeutics stock or one of its competitors? MarketBeat compares Tvardi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tvardi Therapeutics include Aldeyra Therapeutics (ALDX), Aadi Bioscience (AADI), JATT Acquisition (JATT), Biomea Fusion (BMEA), and Kalaris Therapeutics (KLRS).

How does Tvardi Therapeutics compare to Aldeyra Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Tvardi Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.65	-$18.21M	-$3.10	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics' return on equity of -57.34% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tvardi Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 791.09%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 259.48%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tvardi Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tvardi Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Tvardi Therapeutics' score of 0.16 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tvardi Therapeutics beats Aldeyra Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Aadi Bioscience?

Tvardi Therapeutics (NASDAQ:TVRD) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Tvardi Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.65	-$18.21M	-$3.10	N/A
Aadi Bioscience	$25.07M	3.79	-$65.76M	-$2.35	N/A

Tvardi Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, Tvardi Therapeutics had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 0 mentions for Aadi Bioscience. Tvardi Therapeutics' average media sentiment score of 0.16 beat Aadi Bioscience's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tvardi Therapeutics	Neutral
Aadi Bioscience	Neutral

Tvardi Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Tvardi Therapeutics' return on equity of -64.17% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Tvardi Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 791.09%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tvardi Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tvardi Therapeutics beats Aadi Bioscience on 11 of the 17 factors compared between the two stocks.

How does Tvardi Therapeutics compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Tvardi Therapeutics (NASDAQ:TVRD) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Tvardi Therapeutics had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 1 mentions for JATT Acquisition. Tvardi Therapeutics' average media sentiment score of 0.16 beat JATT Acquisition's score of -1.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Negative
Tvardi Therapeutics	Neutral

JATT Acquisition has higher earnings, but lower revenue than Tvardi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Tvardi Therapeutics	$7.14M	2.65	-$18.21M	-$3.10	N/A

Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 791.09%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

JATT Acquisition's return on equity of -49.58% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Summary

Tvardi Therapeutics beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Biomea Fusion?

Tvardi Therapeutics (NASDAQ:TVRD) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Tvardi Therapeutics presently has a consensus target price of $18.00, indicating a potential upside of 791.09%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 608.33%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tvardi Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tvardi Therapeutics' return on equity of -64.17% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Biomea Fusion	N/A	-265.37%	-103.96%

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Biomea Fusion. Tvardi Therapeutics' average media sentiment score of 0.16 beat Biomea Fusion's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tvardi Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.65	-$18.21M	-$3.10	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Tvardi Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Biomea Fusion on 11 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Kalaris Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Kalaris Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.16 beat Kalaris Therapeutics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tvardi Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.65	-$18.21M	-$3.10	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Tvardi Therapeutics' return on equity of -64.17% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

Tvardi Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Tvardi Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 791.09%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 362.96%. Given Tvardi Therapeutics' higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Tvardi Therapeutics beats Kalaris Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.70M	$11.61B	$6.86B	$12.43B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-0.65	793.98	280.72	24.99
Price / Sales	2.65	939.90	645.01	112.42
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	0.91	10.33	10.94	6.21
Net Income	-$18.21M	$2.80B	$3.48B	$347.49M
7 Day Performance	-17.21%	0.67%	0.80%	1.28%
1 Month Performance	N/A	-3.87%	-4.17%	-3.62%
1 Year Performance	-92.33%	154.66%	61.47%	18.37%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	3.115 of 5 stars	$2.02 -3.8%	$18.00 +791.1%	-92.3%	$19.70M	$7.14M	N/A	80
ALDX Aldeyra Therapeutics	3.5627 of 5 stars	$1.52 -1.9%	$5.50 +261.8%	-68.2%	$91.69M	N/A	N/A	10	Upcoming Earnings
AADI Aadi Bioscience	N/A	$3.71 -3.1%	N/A	+121.3%	$91.63M	$25.07M	N/A	40
JATT JATT Acquisition	N/A	$11.31 +3.7%	N/A	+720.0%	$90.76M	N/A	N/A	3	Negative News
BMEA Biomea Fusion	1.846 of 5 stars	$1.25 -0.8%	$8.50 +580.0%	-23.6%	$90.37M	N/A	N/A	50	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. ALDX, AADI, JATT, BMEA, and KLRS

How does Tvardi Therapeutics compare to Aldeyra Therapeutics?

Summary

How does Tvardi Therapeutics compare to Aadi Bioscience?

Summary

How does Tvardi Therapeutics compare to JATT Acquisition?

Summary

How does Tvardi Therapeutics compare to Biomea Fusion?

Summary

How does Tvardi Therapeutics compare to Kalaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. ALDX, AADI, JATT, BMEA, and KLRS

How does Tvardi Therapeutics compare to Aldeyra Therapeutics?

Which has preferable earnings and valuation, TVRD or ALDX?

Is TVRD or ALDX more profitable?

Do insiders & institutionals have more ownership in TVRD or ALDX?

Do analysts recommend TVRD or ALDX?

Which has more risk and volatility, TVRD or ALDX?

Does the media refer more to TVRD or ALDX?

Summary

How does Tvardi Therapeutics compare to Aadi Bioscience?

Which has better valuation & earnings, TVRD or AADI?

Which has more risk and volatility, TVRD or AADI?

Does the media favor TVRD or AADI?

Is TVRD or AADI more profitable?

Do analysts rate TVRD or AADI?

Do insiders and institutionals have more ownership in TVRD or AADI?

Summary

How does Tvardi Therapeutics compare to JATT Acquisition?

Does the media refer more to JATT or TVRD?

Which has better earnings and valuation, JATT or TVRD?

Do analysts prefer JATT or TVRD?

Do institutionals & insiders believe in JATT or TVRD?

Is JATT or TVRD more profitable?

Summary

How does Tvardi Therapeutics compare to Biomea Fusion?

Do analysts rate TVRD or BMEA?

Is TVRD or BMEA more profitable?

Does the media prefer TVRD or BMEA?

Do institutionals & insiders hold more shares of TVRD or BMEA?

Which has stronger earnings & valuation, TVRD or BMEA?

Which has more volatility & risk, TVRD or BMEA?

Summary

How does Tvardi Therapeutics compare to Kalaris Therapeutics?

Does the media favor TVRD or KLRS?

Do insiders and institutionals have more ownership in TVRD or KLRS?

Which has higher earnings and valuation, TVRD or KLRS?

Is TVRD or KLRS more profitable?

Which has more risk & volatility, TVRD or KLRS?

Do analysts rate TVRD or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools